BACKGROUND: Inflammation plays a central role in peritoneal carcinomatosis (PC) etiology and progression, and circulating levels of inflammatory biomarkers prior to surgery predict progression-free and overall survival in PC patients. Depression and fatigue are prevalent among PC patients, and experimental research shows that these symptoms may be mediated by proinflammatory cytokines. As yet unstudied is the possibility that the heightened levels of inflammatory markers in PC patients may contribute to their experience of common neurovegetative symptoms. METHODS: Validated self-report measures of fatigue, depressive symptoms, and quality of life were administered to 64 patients scheduled to undergo aggressive surgical treatment for PC. Serum samples were collected the morning of surgery, and ELISAs were conducted to quantify circulating IL-6, CRP, and TNF-α levels. RESULTS: Consistent with hypotheses, higher IL-6 levels were associated with more severe fatigue (β=-.39, p<.01) and neurovegetative symptoms of depression (β=.30, p<.05). IL-6 was also related to poorer physical quality of life (β=-.28, p<.05). CRP showed similar significant relationships with fatigue and physical quality of life. Inflammatory biomarkers were not significantly related to emotional symptoms of depression or to emotional or social functioning aspects of quality of life, and TNF-α levels were not related to patient-reported measures. CONCLUSION: Preoperative inflammatory activity may contribute to patients' experiences of fatigue and neurovegetative depressive symptoms as well as impaired quality of life. These biological mechanisms warrant consideration in the clinical management of neurovegetative symptoms in PC patients.
BACKGROUND:Inflammation plays a central role in peritoneal carcinomatosis (PC) etiology and progression, and circulating levels of inflammatory biomarkers prior to surgery predict progression-free and overall survival in PC patients. Depression and fatigue are prevalent among PC patients, and experimental research shows that these symptoms may be mediated by proinflammatory cytokines. As yet unstudied is the possibility that the heightened levels of inflammatory markers in PC patients may contribute to their experience of common neurovegetative symptoms. METHODS: Validated self-report measures of fatigue, depressive symptoms, and quality of life were administered to 64 patients scheduled to undergo aggressive surgical treatment for PC. Serum samples were collected the morning of surgery, and ELISAs were conducted to quantify circulating IL-6, CRP, and TNF-α levels. RESULTS: Consistent with hypotheses, higher IL-6 levels were associated with more severe fatigue (β=-.39, p<.01) and neurovegetative symptoms of depression (β=.30, p<.05). IL-6 was also related to poorer physical quality of life (β=-.28, p<.05). CRP showed similar significant relationships with fatigue and physical quality of life. Inflammatory biomarkers were not significantly related to emotional symptoms of depression or to emotional or social functioning aspects of quality of life, and TNF-α levels were not related to patient-reported measures. CONCLUSION: Preoperative inflammatory activity may contribute to patients' experiences of fatigue and neurovegetative depressive symptoms as well as impaired quality of life. These biological mechanisms warrant consideration in the clinical management of neurovegetative symptoms in PC patients.
Authors: D L Musselman; A H Miller; M R Porter; A Manatunga; F Gao; S Penna; B D Pearce; J Landry; S Glover; J S McDaniel; C B Nemeroff Journal: Am J Psychiatry Date: 2001-08 Impact factor: 18.112
Authors: Jennifer K Pai; Tobias Pischon; Jing Ma; JoAnn E Manson; Susan E Hankinson; Kaumudi Joshipura; Gary C Curhan; Nader Rifai; Carolyn C Cannuscio; Meir J Stampfer; Eric B Rimm Journal: N Engl J Med Date: 2004-12-16 Impact factor: 91.245
Authors: Lucile Capuron; Jane F Gumnick; Dominique L Musselman; David H Lawson; Andrea Reemsnyder; Charles B Nemeroff; Andrew H Miller Journal: Neuropsychopharmacology Date: 2002-05 Impact factor: 7.853
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Robert Dantzer; Jason C O'Connor; Gregory G Freund; Rodney W Johnson; Keith W Kelley Journal: Nat Rev Neurosci Date: 2008-01 Impact factor: 34.870
Authors: Niraj J Gusani; Sung W Cho; Christos Colovos; Songwon Seo; Jan Franko; Scott D Richard; Robert P Edwards; Charles K Brown; Matthew P Holtzman; Herbert J Zeh; David L Bartlett Journal: Ann Surg Oncol Date: 2007-12-12 Impact factor: 5.344
Authors: Daniel C McFarland; Meredith Doherty; Thomas M Atkinson; Robin O'Hanlon; William Breitbart; Christian J Nelson; Andrew H Miller Journal: Cancer Date: 2022-04-13 Impact factor: 6.921